Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

A new study outlines that most of the benefits of hormone therapy for prostate cancer occur in the first 9 to 12 months, and ...

Androgen-deprivation therapy (ADT) has become the mainstay of treatment for metastatic prostate cancer. ADT's testosterone depletion, however, leads to side effects that impair health-related ...

(HealthDay News) — Older men who receive androgen deprivation therapy (ADT) for prostate cancer may be at increased risk of developing depression, according to a new, large study published online in ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is ...

April 30, 2009 — Androgen-deprivation therapy (ADT) is a common treatment for men with prostate cancer, but patients who do undergo this therapy are at an increased risk for skeletal fracture, ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of ...